

Maurizio Averna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8884668/publications.pdf>

Version: 2024-02-01

277
papers

15,703
citations

34076

52
h-index

19169

118
g-index

286
all docs

286
docs citations

286
times ranked

13368
citing authors

#	ARTICLE	IF	CITATIONS
1	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	1.0	2,132
2	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1489-1499.	13.9	1,838
3	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
4	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
5	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. <i>Lancet</i> , 2013, 381, 40-46.	6.3	624
6	Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1990, 322, 1769-1774.	13.9	565
7	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
8	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
9	A novel component of the metabolic syndrome: The oxidative stress. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 72-77.	1.1	292
10	Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 247-251.	1.1	244
11	A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2221.	3.8	227
12	Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children. <i>Clinical Chemistry</i> , 2003, 49, 861-867.	1.5	192
13	Increased thromboxane biosynthesis in type IIa hypercholesterolemia.. <i>Circulation</i> , 1992, 85, 1792-1798.	1.6	174
14	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. <i>Atherosclerosis</i> , 2016, 244, 138-146.	0.4	163
15	Estrogen Up-regulates Apolipoprotein E (ApoE) Gene Expression by Increasing ApoE mRNA in the Translating Pool via the Estrogen Receptor α -Mediated Pathway. <i>Journal of Biological Chemistry</i> , 1997, 272, 33360-33366.	1.6	158
16	Gastrointestinal symptoms in infancy: A population-based prospective study. <i>Digestive and Liver Disease</i> , 2005, 37, 432-438.	0.4	152
17	Molecular diagnosis of hypobetalipoproteinemia: An ENID review. <i>Atherosclerosis</i> , 2007, 195, e19-e27.	0.4	152
18	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , 2018, 275, 265-272.	0.4	131

#	ARTICLE	IF	CITATIONS
19	Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. <i>Atherosclerosis</i> , 2013, 227, 342-348.	0.4	128
20	Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. <i>Journal of Lipid Research</i> , 2003, 44, 470-478.	2.0	127
21	A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 677-681.	1.1	125
22	Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, E41-52.	1.1	122
23	Comparison of Anti-Transglutaminase ELISAs and an Anti-Endomysial Antibody Assay in the Diagnosis of Celiac Disease: A Prospective Study. <i>Clinical Chemistry</i> , 2002, 48, 1546-1550.	1.5	120
24	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 50-67.	5.5	114
25	Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins. <i>Free Radical Biology and Medicine</i> , 2007, 43, 1255-1262.	1.3	110
26	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 332-335.	1.6	103
27	Hypobetalipoproteinemia. <i>Advances in Clinical Chemistry</i> , 2011, 54, 81-107.	1.8	101
28	Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. <i>Atherosclerosis</i> , 2006, 186, 433-440.	0.4	97
29	Diagnostic algorithm for familial chylomicronemia syndrome. <i>Atherosclerosis Supplements</i> , 2017, 23, 1-7.	1.2	94
30	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 58, 629-636.	1.2	91
31	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
32	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.4	83
33	Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 805-809.	1.1	80
34	Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. <i>Thrombosis Research</i> , 1982, 26, 359-370.	0.8	78
35	Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. <i>Atherosclerosis</i> , 2004, 174, 57-65.	0.4	77
36	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. <i>Journal of Lipid Research</i> , 2013, 54, 3481-3490.	2.0	76

#	ARTICLE	IF	CITATIONS
37	The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. <i>Human Mutation</i> , 2006, 27, 460-466.	1.1	74
38	Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 828-837.	1.9	74
39	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. <i>Atherosclerosis</i> , 2010, 208, 177-182.	0.4	74
40	A Novel <i>APOB</i> Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2021-2025.	1.1	73
41	A Targeted Apolipoprotein B-38.9-producing Mutation Causes Fatty Livers in Mice Due to the Reduced Ability of Apolipoprotein B-38.9 to Transport Triglycerides. <i>Journal of Biological Chemistry</i> , 2000, 275, 32807-32815.	1.6	71
42	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet</i> , 2022, 399, 719-728.	6.3	69
43	Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: A multicenter Italian study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 84-90.	1.1	68
44	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
45	Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1441-1446.	1.1	64
46	Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. <i>International Journal of Clinical Practice</i> , 2009, 63, 547-559.	0.8	62
47	Platelet Sensitivity to Prostacyclin and Thromboxane Production in Hyperlipidemic Patients. <i>Thrombosis and Haemostasis</i> , 1982, 48, 018-020.	1.8	61
48	Mutations in MTP gene in alpha- and hypobeta-lipoproteinemia. <i>Atherosclerosis</i> , 2005, 180, 311-318.	0.4	60
49	Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. <i>Journal of Internal Medicine</i> , 2007, 262, 104-112.	2.7	60
50	Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat Î²-Cells. Direct Effect of Oxidative Stress. <i>Scientific Reports</i> , 2017, 7, 11863.	1.6	59
51	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. <i>Advances in Therapy</i> , 2017, 34, 1200-1210.	1.3	56
52	Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. <i>Atherosclerosis</i> , 2015, 241, 79-86.	0.4	55
53	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
54	Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. <i>FEBS Journal</i> , 2000, 267, 4272-4280.	0.2	52

#	ARTICLE	IF	CITATIONS
55	Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4584-4590.	1.8	52
56	The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. <i>Diabetes Care</i> , 2013, 36, 2850-2856.	4.3	51
57	Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. <i>International Journal of Obesity</i> , 2001, 25, 185-190.	1.6	49
58	Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. <i>Acta Diabetologica</i> , 2013, 50, 241-249.	1.2	48
59	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.4	48
60	Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. <i>Atherosclerosis</i> , 2004, 172, 309-320.	0.4	47
61	Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. <i>Atherosclerosis</i> , 1989, 79, 79-83.	0.4	46
62	Chronic constipation and food intolerance: A model of proctitis causing constipation. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 33-42.	0.6	46
63	Autoimmune enteropathy and colitis in an adult patient. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1600-1606.	1.1	45
64	Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2013, 112, 1885-1895.	0.7	45
65	Exome Sequencing in Suspected Monogenic Dyslipidemias. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 343-350.	5.1	45
66	Under-prescription of statins in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 161-167.	1.1	45
67	Gelatinases and Their Tissue Inhibitors in a Group of Subjects With Metabolic Syndrome. <i>Journal of Investigative Medicine</i> , 2013, 61, 978-983.	0.7	43
68	The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: Results of a 15 years follow-up in a Mediterranean population. <i>Atherosclerosis</i> , 2008, 197, 147-153.	0.4	42
69	Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 2002, 335, 147-149.	1.0	40
70	Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. <i>Journal of Clinical Lipidology</i> , 2015, 9, 607-617.	0.6	40
71	Autosomal Recessive Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 71, 279-288.	1.2	38
72	CAROTID ATHEROSCLEROSIS IN RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, 366-371.	0.5	37

#	ARTICLE	IF	CITATIONS
73	Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. <i>Clinical Chemistry</i> , 2002, 48, 1546-50.	1.5	37
74	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trial. <i>Atherosclerosis</i> , 2015, 240, 408-414.	0.4	36
75	Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. <i>Journal of Lipid Research</i> , 1999, 40, 955-959.	2.0	36
76	Association of estrogen receptor β gene with Alzheimer's disease: A case-control study. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 273-278.	1.2	35
77	Analysis of sterols by high-performance liquid chromatography/mass spectrometry combined with chemometrics. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 2433-2440.	0.7	35
78	Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. <i>Journal of Translational Medicine</i> , 2012, 10, 235.	1.8	35
79	Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up. <i>Atherosclerosis</i> , 2001, 157, 225-231.	0.4	34
80	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1234-1242.	0.6	34
81	Association between apolipoprotein E e4 allele and apathy in probable Alzheimer's disease.. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 59-63.	2.2	33
82	The pathophysiology of intestinal lipoprotein production. <i>Frontiers in Physiology</i> , 2015, 6, 61.	1.3	33
83	Unexplained Elevated Serum Pancreatic Enzymes: A Reason to Suspect Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 455-459.	2.4	32
84	Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. <i>Advances in Clinical Chemistry</i> , 2011, 54, 81-107.	1.8	32
85	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. <i>Atherosclerosis</i> , 2018, 271, 120-127.	0.4	31
86	eNOS Activation by HDL Is Impaired in Genetic CETP Deficiency. <i>PLoS ONE</i> , 2014, 9, e95925.	1.1	31
87	Nutritional Characteristics of a Rural Southern Italy Population: The Ventimiglia di Sicilia Project. <i>Journal of the American College of Nutrition</i> , 2002, 21, 523-529.	1.1	30
88	C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. <i>Clinical Biochemistry</i> , 2009, 42, 1713-1718.	0.8	30
89	Thrombin-antithrombin III complexes in type II diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1992, 6, 7-11.	1.2	29
90	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3340-3348.	1.8	29

#	ARTICLE	IF	CITATIONS
91	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	1.0	29
92	Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1015-1019.	1.8	29
93	Cystatin C levels are decreased in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 101, 213-217.	0.8	28
94	Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low-HDL Phenotype. <i>Journal of the American Heart Association</i> , 2013, 2, e000063.	1.6	28
95	Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 822-829.	1.1	28
96	Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. <i>Journal of Lipid Research</i> , 1999, 40, 955-9.	2.0	28
97	Liver is not the unique site of synthesis of β 2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization. <i>International Journal of Clinical and Laboratory Research</i> , 1997, 27, 207-212.	1.0	27
98	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis Supplements</i> , 2014, 15, 33-45.	1.2	27
99	Multiple food hypersensitivity as a cause of refractory chronic constipation in adults. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 498-504.	0.6	26
100	Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. <i>Atherosclerosis</i> , 2009, 204, 202-207.	0.4	26
101	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. <i>Clinical Chemistry</i> , 1998, 44, 1388-1396.	1.5	25
102	No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 2003, 341, 229-232.	1.0	25
103	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. <i>Atherosclerosis</i> , 2020, 312, 72-78.	0.4	25
104	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017, 26, 16-24.	1.2	24
105	Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. <i>Journal of Lipid Research</i> , 2002, 43, 407-415.	2.0	24
106	Plasma Lipid, Apolipoprotein and Lp(a) Levels in Elderly Normolipidemic Women: Relationships with Coronary Heart Disease and Longevity. <i>Gerontology</i> , 1995, 41, 260-266.	1.4	23
107	ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. <i>European Journal of Epidemiology</i> , 2001, 17, 707-713.	2.5	23
108	Factor VII Activity Is an Independent Predictor of Cardiovascular Mortality in Elderly Women of a Sicilian Population: Results of an 11-year Follow-up. <i>Thrombosis and Haemostasis</i> , 2002, 87, 206-210.	1.8	23

#	ARTICLE	IF	CITATIONS
109	Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. <i>Atherosclerosis</i> , 2003, 166, 395-400.	0.4	23
110	Anti-Actin Antibodies in Celiac Disease: Correlation with Intestinal Mucosa Damage and Comparison of ELISA with the Immunofluorescence Assay. <i>Clinical Chemistry</i> , 2005, 51, 917-920.	1.5	23
111	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1647-1650.	1.1	23
112	Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. <i>Journal of Lipid Research</i> , 2002, 43, 407-15.	2.0	23
113	Lipoprotein Profile and High-Density Lipoproteins: Subfractions Distribution in Centenarians. <i>Gerontology</i> , 1998, 44, 106-110.	1.4	22
114	The C(-260)>T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction. <i>Clinical and Experimental Medicine</i> , 2003, 3, 161-165.	1.9	22
115	Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. <i>Atherosclerosis</i> , 2009, 206, 193-198.	0.4	22
116	Role of Nutraceuticals in Hypolipidemic Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2015, 2, 22.	1.1	22
117	A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach-Wiethe disease) from Sicily. <i>British Journal of Dermatology</i> , 2005, 153, 1019-1022.	1.4	21
118	Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 463-467.	1.5	21
119	Lipase maturation factor 1 is required for endothelial lipase activity. <i>Journal of Lipid Research</i> , 2011, 52, 1162-1169.	2.0	21
120	Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2012, 6, 132-135.	1.8	21
121	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. <i>Journal of Internal Medicine</i> , 2021, 290, 116-128.	2.7	21
122	Determinants of enhanced thromboxane biosynthesis in renal transplantation. <i>Kidney International</i> , 2001, 59, 1574-1579.	2.6	20
123	Estrogen increases hepatic lipase levels in inbred strains of mice: a possible mechanism for estrogen-dependent lowering of high density lipoprotein. <i>Molecular and Cellular Biochemistry</i> , 2001, 220, 87-93.	1.4	20
124	Obesity and the metabolic syndrome in a student cohort from Southern Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 620-625.	1.1	20
125	Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2014, 16, 414.	2.0	20
126	Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 347-354.	0.6	20

#	ARTICLE	IF	CITATIONS
127	Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2694-2699.	1.1	20
128	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 662-668.	1.5	19
129	The effect of ezetimibe on NAFLD. <i>Atherosclerosis Supplements</i> , 2015, 17, 27-34.	1.2	19
130	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017, 262, 179-184.	0.4	19
131	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature. <i>Acta Diabetologica</i> , 2017, 54, 111-122.	1.2	19
132	Postprandial lipemia in subjects with hypobetalipoproteinemia and a single intestinal allele for apoB-48. <i>Journal of Lipid Research</i> , 1993, 34, 1957-1967.	2.0	19
133	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017, 19, D3-D54.	0.0	19
134	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1864-1872.	0.8	19
135	Postprandial lipemia in subjects with hypobetalipoproteinemia and a single intestinal allele for apoB-48. <i>Journal of Lipid Research</i> , 1993, 34, 1957-67.	2.0	19
136	Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: A comparison with type IV hyperlipoproteinemic patients. <i>Metabolism: Clinical and Experimental</i> , 1989, 38, 601-602.	1.5	18
137	Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. <i>Journal of Clinical Lipidology</i> , 2017, 11, 272-281.e8.	0.6	18
138	The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. <i>Atherosclerosis</i> , 2017, 262, 146-153.	0.4	18
139	Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. <i>Journal of Lipid Research</i> , 1999, 40, 901-912.	2.0	18
140	A new apolipoprotein B truncation (apo B-43.7) in familial hypobetalipoproteinemia: Genetic and metabolic studies. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1296-1304.	1.5	17
141	Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. <i>Molecular and Cellular Biochemistry</i> , 1999, 202, 37-46.	1.4	17
142	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 89, 460-462.	0.7	17
143	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. <i>Atherosclerosis</i> , 2015, 239, 209-217.	0.4	17
144	Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia. <i>Annals of Hepatology</i> , 2011, 10, 221-226.	0.6	16

#	ARTICLE	IF	CITATIONS
145	Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 36-44.	1.1	16
146	Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particles trapping to cell surface proteoglycans in a liver hepatoma cell model. <i>Atherosclerosis</i> , 2016, 246, 50-56.	0.4	16
147	Liver and Statins: A Critical Appraisal of the Evidence. <i>Current Medicinal Chemistry</i> , 2019, 25, 5835-5846.	1.2	16
148	Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. <i>Kidney International</i> , 1999, 55, 2433-2439.	2.6	15
149	Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 31, 57-62.	0.6	15
150	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1308-1316.	1.5	15
151	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1362-1367.	1.8	15
152	Plasma Non-cholesterol Sterols: A Useful Diagnostic Tool in Pediatric Hypercholesterolemia. <i>Pediatric Research</i> , 2010, 67, 200-204.	1.1	15
153	Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. <i>Cardiovascular Therapeutics</i> , 2012, 30, 61-74.	1.1	15
154	Lipid Peroxidation, Nitric Oxide Metabolites, and Their Ratio in a Group of Subjects with Metabolic Syndrome. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-8.	1.9	15
155	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. <i>European Journal of Human Genetics</i> , 2015, 23, 381-387.	1.4	15
156	A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G1170-G1176.	1.6	14
157	Baseline metabolic disturbances and the twenty-five years risk of incident cancer in a Mediterranean population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1020-1025.	1.1	14
158	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.	1.0	14
159	Platelet function in patients with type 2 diabetes mellitus: the effect of glycaemic control. <i>Diabetes Research</i> , 1989, 10, 7-12.	0.1	14
160	Enhanced Platelet Release Reaction in Insulin-Dependent and Insulin-Independent Diabetic Patients. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1982, 12, 275-281.	0.5	13
161	Familial Hypobetalipoproteinemia Is Not Associated With Low Levels of Lipoprotein(a). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 2165-2175.	1.1	13
162	Screening for celiac disease in non-Hodgkin's lymphoma patients: a serum anti-transglutaminase-based approach. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1530-1536.	1.1	13

#	ARTICLE	IF	CITATIONS
163	NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR- α and LXR agonists. <i>Molecular and Cellular Biochemistry</i> , 2020, 473, 247-262.	1.4	13
164	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. <i>Archives of Medical Science</i> , 2022, 18, 285-292.	0.4	13
165	Two Italian kindreds carrying the Arg136 \rightarrow Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2003, 13, 93-99.	1.1	12
166	Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 262-270.	0.9	12
167	Protein oxidation in a group of subjects with metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2013, 7, 38-41.	1.8	12
168	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.	1.2	12
169	Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. <i>Journal of Lipid Research</i> , 1999, 40, 901-12.	2.0	12
170	Twelve Variants Polygenic Score for Low-density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. <i>Journal of the American Heart Association</i> , 2022, 11, e023668.	1.6	12
171	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 361-367.	1.1	11
172	Lomitapide: a novel drug for homozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2014, 9, 19-32.	0.4	11
173	Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up. <i>Indian Journal of Gastroenterology</i> , 2016, 35, 236-241.	0.7	11
174	Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases. <i>Life</i> , 2021, 11, 581.	1.1	11
175	Apolipoprotein profile in type II diabetic patients with and without coronary heart disease. <i>Acta Diabetologica Latina</i> , 1990, 27, 371-377.	0.2	10
176	Follow-Up of Lipid and Apoprotein Levels in Renal Transplant Recipients. <i>Nephron</i> , 1991, 58, 255-256.	0.9	10
177	Plasma levels of lipoproteins and apolipoproteins in congenital hypothyroidism: Effects of l-thyroxine substitution therapy. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 1283-1287.	1.5	10
178	No association between the cystatin C gene polymorphism and Alzheimer's disease: A case-control study in an Italian population. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 291-295.	1.2	10
179	Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 321-326.	1.1	10
180	Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. <i>Journal of Clinical Lipidology</i> , 2010, 4, 272-278.	0.6	10

#	ARTICLE	IF	CITATIONS
181	Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study. <i>Acta Diabetologica</i> , 2012, 49, 145-151.	1.2	10
182	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disease progression by aspirin in diabetic patients (LEDA) trial. Rationale and study design. <i>American Heart Journal</i> , 2017, 189, 120-127.	1.2	10
183	Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis. <i>Frontiers in Physiology</i> , 2018, 9, 1222.	1.3	10
184	Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1068-1076.	1.1	10
185	Left ventricular hypertrophy in chronic kidney disease: A diagnostic criteria comparison. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 137-144.	1.1	10
186	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2020, 42, e35-e40.	1.2	10
187	Lomitapide affects HDL composition and function. <i>Atherosclerosis</i> , 2016, 251, 15-18.	0.4	9
188	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. <i>Cardiovascular Research</i> , 2018, 114, 1595-1604.	1.8	9
189	Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. <i>Endocrine</i> , 2021, 71, 344-350.	1.1	9
190	Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 1297-1305.	1.2	8
191	Plasma non-cholesterol sterols in primary hypobetalipoproteinemia. <i>Atherosclerosis</i> , 2011, 216, 409-413.	0.4	8
192	Lipid and Apoprotein Composition of HDL in Partial or Complete CETP Deficiency. <i>Current Vascular Pharmacology</i> , 2012, 10, 422-431.	0.8	8
193	Inverse association between type 2 diabetes and aortic root dimension in hypertensive patients. <i>International Journal of Cardiology</i> , 2017, 228, 233-237.	0.8	8
194	Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred. <i>Journal of Clinical Lipidology</i> , 2018, 12, 145-151.	0.6	8
195	Is echocardiography mandatory for patients with chronic kidney disease?. <i>Internal and Emergency Medicine</i> , 2019, 14, 923-929.	1.0	8
196	Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. <i>Life</i> , 2021, 11, 315.	1.1	8
197	Prevalence Of familial hypercholesterolaemia (FH) in Italian Patients with coronary artery disease: The POSTER study. <i>Atherosclerosis</i> , 2020, 308, 32-38.	0.4	8
198	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. <i>International Journal of Molecular Medicine</i> , 2006, 18, 449-55.	1.8	8

#	ARTICLE	IF	CITATIONS
199	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. <i>Clinica Chimica Acta</i> , 1994, 224, 111-118.	0.5	7
200	Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 1995, 10, 96-100.	0.7	7
201	Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB-48 synthesis in a hypobetalipoproteinemic kindred without any ApoB truncation. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 1095-1100.	1.5	7
202	Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2001, 33, 1215-1226.	1.2	7
203	rs629301 CELSR2 polymorphism confers a ten-year equivalent risk of critical stenosis assessed by coronary angiography. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1542-1547.	1.1	7
204	Gene expression in mouse spermatogenesis during ontogenesis. <i>International Journal of Molecular Medicine</i> , 2006, 17, 523-8.	1.8	7
205	Platelet activation after adrenergic stimulation in hypertensive patients: effects of acebutolol. <i>European Heart Journal</i> , 1983, 4, 295-299.	1.0	6
206	HDL Subtractions Distribution in Renal Transplant Recipients: Lack of Evidence of a Reduction of HDL₂ Particles. <i>Nephron</i> , 1996, 72, 407-412.	0.9	6
207	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. <i>International Journal of Molecular Medicine</i> , 2006, 18, 449.	1.8	6
208	The production of 85kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apob gene occurs by ALLN-inhibitable protease cleavage during translocation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 665-670.	1.0	6
209	Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. <i>Lipids in Health and Disease</i> , 2010, 9, 127.	1.2	6
210	Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertriglyceridemia and recurrent hyperlipidemic pancreatitis. <i>Transfusion</i> , 2016, 56, 755-760.	0.8	6
211	Lipoprotein-associated phospholipase A ₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 517-523.	1.1	6
212	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study. <i>Atherosclerosis</i> , 2020, 292, 209-214.	0.4	6
213	Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1015-9.	1.8	6
214	Clinical utility of novel biomarkers for cardiovascular disease risk stratification. <i>Internal and Emergency Medicine</i> , 2012, 7, 263-270.	1.0	5
215	Familial combined hypolipidemia due to mutations in the <i>ANGPTL3</i> gene. <i>Clinical Lipidology</i> , 2013, 8, 81-95.	0.4	5
216	Behavior of the total antioxidant status in a group of subjects with metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 166-169.	1.8	5

#	ARTICLE	IF	CITATIONS
217	Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients. <i>Hemodialysis International</i> , 2015, 19, 360-367.	0.4	5
218	Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 371-379.	1.2	5
219	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. <i>Atherosclerosis Plus</i> , 2021, 43, 7-9.	0.3	5
220	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 721-729.	0.8	5
221	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients. <i>Atherosclerosis</i> , 2022, 347, 63-67.	0.4	5
222	A Novel Mutation of the DHCR7 Gene in a Sicilian Compound Heterozygote with Smith-Lemli-Opitz Syndrome. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 201-204.	1.2	4
223	Down regulation of CD11b and CD18 expression in children with hypercholesterolemia: A preliminary report. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 105-109.	1.1	4
224	Issues Affecting Quality of Life and Disease Burden in Lipoprotein Lipase Deficiency (Lpld) – First Step Towards a Pro Measure in Lpld. <i>Value in Health</i> , 2015, 18, A707.	0.1	4
225	FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheimer's disease. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 2215-2226.	1.9	4
226	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018, 21, 1334-1336.	0.5	4
227	Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 17-20.	1.1	4
228	One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?. <i>European Journal of Internal Medicine</i> , 2022, 95, 1-4.	1.0	4
229	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. <i>Clinical Chemistry</i> , 1998, 44, 1388-96.	1.5	4
230	Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. <i>International Journal of Molecular Medicine</i> , 2006, 17, 539-46.	1.8	4
231	Diagnostic use of fructosamine assay in the control of type II diabetes mellitus. <i>Acta Diabetologica Latina</i> , 1988, 25, 63-68.	0.2	3
232	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. <i>Clinica Chimica Acta</i> , 2003, 328, 91-97.	0.5	3
233	Statins and metabolic syndrome. <i>International Congress Series</i> , 2003, 1253, 243-246.	0.2	3
234	CETP levels rather than polymorphisms as markers of coronary risk: Healthy athlete with high HDL-C and coronary disease – effectiveness of probucol. <i>Atherosclerosis</i> , 2006, 186, 225-227.	0.4	3

#	ARTICLE	IF	CITATIONS
235	Prevalence of "Borderline" Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 43-51.	1.0	3
236	Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. Combination Products in Therapy, 2011, 1, 1.	1.1	3
237	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical Biochemistry, 2011, 44, 627-634.	0.8	3
238	Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regulated at the transcriptional level. Journal of Diabetes and Metabolic Disorders, 2020, 19, 363-371.	0.8	3
239	Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. Current Medicinal Chemistry, 2020, 27, 3773-3783.	1.2	3
240	LifeStyle versus Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	3
241	Comparison of two polygenic risk scores to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects. Journal of Clinical Lipidology, 2022, 16, 530-537.	0.6	3
242	New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	3
243	Effects of gemfibrozil in hyperlipidemic patients with or without diabetes. Current Therapeutic Research, 1993, 53, 381-393.	0.5	2
244	Rapid screening of the LDL receptor point mutation FH-Genoa/Palermo. , 1999, 13, 412-412.		2
245	Genetics of familial hypobetalipoproteinemia. Future Lipidology, 2007, 2, 615-624.	0.5	2
246	Statin therapy in patients with aortic stenosis after the ASTRONOMER trial: is there still any space?. Internal and Emergency Medicine, 2012, 7, 35-36.	1.0	2
247	Oxidative status in nondiabetic middle-aged subjects with metabolic syndrome: Preliminary data. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, e17-e18.	1.1	2
248	Differences in Cardiac Structure and Function Between Black and White Patients: Another Step in the Evaluation of Cardiovascular Risk in Chronic Kidney Disease. American Journal of Hypertension, 2017, 30, 770-771.	1.0	2
249	Resistive index of ophthalmic artery as an imaging biomarker of hypertension-related vascular and kidney damage. Biomarkers in Medicine, 2021, 15, 1155-1166.	0.6	2
250	A Novel Mutation of the DHCR7 Gene in a Sicilian Compound Heterozygote with Smith-Lemli-Opitz Syndrome. Molecular Diagnosis and Therapy, 2005, 9, 201-204.	1.2	2
251	Transient Neonatal Hypercholesterolemia. Hormone and Metabolic Research, 1993, 25, 271-274.	0.7	1
252	First interim results of the global, longitudinal, pharmaco-epidemiologic, observational registry on gene therapy in the management of lipoprotein lipase deficiency (geniall). Atherosclerosis, 2017, 263, e66-e67.	0.4	1

#	ARTICLE	IF	CITATIONS
253	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019, 13, 735-743.	0.6	1
254	Resting Energy Expenditure and Substrate Oxidation in Malnourished Patients With Type 1 Glycogenosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5566-5572.	1.8	1
255	Automated untargeted stable isotope assisted lipidomics of liver cells on high glucose shows alteration of sphingolipid kinetics. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158656.	1.2	1
256	DeepSRE: Identification of sterol responsive elements and nuclear transcription factors Y proximity in human DNA by Convolutional Neural Network analysis. <i>PLoS ONE</i> , 2021, 16, e0247402.	1.1	1
257	Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia. <i>Internal Medicine Journal</i> , 2021, 51, 585-590.	0.5	1
258	Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. <i>FEBS Journal</i> , 2000, 267, 4272-4280.	0.2	1
259	Correlation between different degree and duration of metabolic control and thyroid hormone levels in type 1 and type 2 diabetics. <i>Acta Diabetologica Latina</i> , 1983, 20, 341-346.	0.2	0
260	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. <i>European Journal of Endocrinology</i> , 2004, 150, 831-836.	1.9	0
261	Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C. <i>Journal of Clinical Lipidology</i> , 2010, 4, 204-205.	0.6	0
262	Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency. <i>Journal of Clinical Lipidology</i> , 2010, 4, 207-208.	0.6	0
263	The ANP Genetic Variant RS5068 is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. <i>Journal of Cardiac Failure</i> , 2012, 18, S65-S66.	0.7	0
264	Response to treatment and occurrence of cardiovascular (cv) complications in patients with autosomal recessive hypercholesterolemia (arh): A retrospective analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, e18-e19.	1.1	0
265	The odyssey apprise trial: rationale, design and interim data. <i>Atherosclerosis</i> , 2017, 263, e25.	0.4	0
266	Characterization of Italian patients with familial hypercholesterolemia: The lipigen study. <i>Atherosclerosis</i> , 2017, 263, e235.	0.4	0
267	An irregular atrial tachycardia. <i>Netherlands Heart Journal</i> , 2018, 26, 102-103.	0.3	0
268	An irregular atrial tachycardia. <i>Netherlands Heart Journal</i> , 2018, 26, 106-108.	0.3	0
269	Clinical and genetic features of familial hypercholesterolemia in pediatric patients: The lipigen Study. <i>Atherosclerosis</i> , 2018, 275, e98-e99.	0.4	0
270	Diabetes and aortic root dimension: A controversial subject. <i>International Journal of Cardiology</i> , 2018, 264, 190.	0.8	0

#	ARTICLE	IF	CITATIONS
271	Mutation in candidate genes account for a small minority of hypobetalipoproteinemias and NGS analysis support polygenicity in mutation-negative patients. <i>Atherosclerosis</i> , 2020, 315, e45.	0.4	0
272	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides. An in vitro study. <i>Atherosclerosis</i> , 2020, 315, e258.	0.4	0
273	Welcome Editorial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1.	1.1	0
274	Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. <i>Atherosclerosis</i> , 2021, 331, e181.	0.4	0
275	ALIROCUMAB EFFICACY AND SAFETY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND WITH OR WITHOUT CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF 10 ODYSSEY RANDOMIZED TRIALS. <i>Canadian Journal of Cardiology</i> , 2017, 33, S115-S116.	0.8	0
276	A novel putative interactor for the low density lipoprotein receptor cytoplasmic domain. <i>Molecular Medicine Reports</i> , 2010, 3, 341-5.	1.1	0
277	Bempedoic Acid: A New Tool for LDL-Cholesterol Control in Patients with Coronary Artery Disease. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 156.	0.5	0